SUPN

Supernus Pharmaceuticals, Inc. (SUPN) Management Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Capital Allocation

Management continues to prioritize balance-sheet strength, with current ratio at 2.08x and debt-to-equity at 0.04x.

Capital deployment remains conservative, as dividend yield is 0% and debt levels are minimal relative to market cap.

Free cash flow generation is still weak, with free cash flow yield at 0.7% and price-to-free-cash-flow at 143.7x.

Execution Operating Discipline

Operating execution remains challenged, with EBIT margin at -14.2% and net margin at -13.2%.

Working-capital efficiency is still poor, reflected in a 381.7-day cash conversion cycle and 309.3 days of inventory outstanding.

Gross margin remains strong at 88.1%, but it is not yet translating into positive operating profitability.

Governance Incentives

No new governance or incentive-related developments were reported this month.

The assessment remains anchored by the company’s conservative leverage profile and ongoing operating losses.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Supernus Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →